银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02591 银诺医药-B

交易中 10-13 11:47:36

3.800

-0.140

-3.55%

最高3.955	最低3.720	成交量321.72万
今开3.955	昨收3.940	日振幅5.96%
总市值17.37亿	流通市值15.97亿	总股本4.57亿
成交额1,225万	换手率0.77%	流通股本4.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"银诺医药-B","latestPrice":3.8,"timestamp":1791863226745,"preClose":3.94,"halted":0,"volume":3217200,"delay":0,"changeRate":-0.0355329949238579,"floatShares":420285370,"shares":457000000,"eps":-0.9257615852462233,"marketStatus":"交易中","change":-0.14,"latestTime":"10-13 11:47:36","open":3.955,"high":3.955,"low":3.72,"amount":12247414,"amplitude":0.059645,"askPrice":3.805,"askSize":2000,"bidPrice":3.8,"bidSize":43000,"shortable":3,"etf":0,"ttmEps":-0.8633078337453405,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1791864000000},"marketStatusCode":2,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":3.94,"openAndCloseTimeList":[[1791855000000,1791864000000],[1791867600000,1791878400000]],"volumeRatio":1.881077,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02591/wiki","defaultTab":"wiki","newsList":[{"id":"1181632949","title":"银诺医药-B：9月股本保持稳定，未有新增发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1181632949","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181632949?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:37","pubTimestamp":1791189452,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司于2026年10月5日发布2026年9月证券变动月报表。报告期为2026年9月1日至9月30日。报告显示，截至2026年9月30日，银诺医药-B注册股本总数为人民币456,819,349元，维持不变。报告期内，上述股份数量均无增减变化。公司在本月并未发生任何新增发行、回购、注销或库藏股等变动。本次公告由公司联席公司秘书杨东妍签署。银诺医药-B重申将继续严格遵守香港联交所《上市规则》及相关法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105926314","title":"银诺医药-B2026年中期营收7,821.80万元 同比增长38.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105926314","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105926314?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:13","pubTimestamp":1790601202,"startTime":"0","endTime":"0","summary":"根据银诺医药-B披露的2026年中期报告，期内实现营收7,821.80万元，同比增长38.56%。报告期内，毛利率为72.50%，相较上年同期89.40%有所下降。从费用结构来看，研发投入为8,529.20万元，相比上年同期的9,908.20万元减少13.90%。销售及分销开支达到6,255.00万元，同比增加42.05%；行政开支为2,670.60万元，同比下降15.36%。经营活动所用现金流量净流出13,536.00万元，上年同期为8,685.20万元，经营性净现金流出同比增加约55.88%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"银诺医药-B2026年中期营收7,821.80万元 同比增长38.56%","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2667666320","title":"黄冰增持银诺医药-B(02591.HK)2400股 每股作价3.89港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666320","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667666320?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:44","pubTimestamp":1789386264,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127325384","title":"银诺医药-B：Cowin Capital Investment III Limited减持，好仓比例降至2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127325384","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127325384?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:23","pubTimestamp":1789118631,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment III Limited于2026年9月10日以每股均价3.8185港元卖出银诺医药-B股份399.00万股，涉资约1523.58万港元。Cowin Capital Investment III Limited此次减持前持有银诺医药-B好仓1441.64万股，占比3.43%；减持后持股量为1042.64万股，好仓比例降至2.48%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196120627","title":"银诺医药-B：Cowin China Growth Fund II, L.P.减持，好仓比例降至2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196120627","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196120627?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:12","pubTimestamp":1789117940,"startTime":"0","endTime":"0","summary":"Cowin China Growth Fund II, L.P.于2026年9月10日以每股均价3.8185港元卖出银诺医药-B股份399.00万股，涉资约1523.58万港元。Cowin China Growth Fund II, L.P.此次减持前持有银诺医药-B好仓1441.64万股，占比3.43%；减持后持股量为1042.64万股，好仓比例降至2.48%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114700606","title":"银诺医药-B：Cowin Capital Investment Limited减持，好仓比例由3.43%降至2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114700606","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114700606?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:46","pubTimestamp":1789033584,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment Limited于2026年9月10日以每股均价3.8185港元卖出银诺医药-B股份399.00万股，涉资约1523.58万港元。Cowin Capital Investment Limited此次减持前持有银诺医药-B好仓1441.64万股，占比3.43%；减持后持股量为1042.64万股，好仓比例降至2.48%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168898987","title":"银诺医药-B：Cowin Capital Investment II LTD减持，好仓比例降至2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168898987","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168898987?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:32","pubTimestamp":1789032777,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment II LTD于2026年9月10日以每股均价3.8185港元卖出银诺医药-B股份399.00万股，涉资约1523.58万港元。Cowin Capital Investment II LTD此次减持前持有银诺医药-B好仓1441.64万股，占比3.43%；减持后持股量为1042.64万股，好仓比例降至2.48%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115796288","title":"银诺医药-B：黄荔减持，好仓比例降至4.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115796288","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115796288?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:22","pubTimestamp":1789032137,"startTime":"0","endTime":"0","summary":"黄荔于2026年9月10日以每股均价3.819港元卖出银诺医药-B（02591）股份519.00万股，涉资约1982.06万港元。黄荔此次减持前持有银诺医药-B好仓2479.11万股，占比5.9%；减持后持股量为1960.11万股，好仓比例降至4.66%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101858139","title":"银诺医药-B：郑伟鹤减持，好仓比例降至4.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101858139","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101858139?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:16","pubTimestamp":1789031770,"startTime":"0","endTime":"0","summary":"于2026年9月10日，郑伟鹤以每股均价3.819港元卖出银诺医药-B股份519.00万股，涉资约1982.06万港元。郑伟鹤此次减持前持有银诺医药-B好仓2479.11万股，占比5.9%；减持后持股量为1960.11万股，好仓比例降至4.66%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180452237","title":"银诺医药-B：郑伟鹤减持，好仓比例降至5.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180452237","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180452237?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:24","pubTimestamp":1788945849,"startTime":"0","endTime":"0","summary":"郑伟鹤于2026年9月8日以每股均价3.6115港元卖出银诺医药-B股份440.00万股，涉资约1589.06万港元。郑伟鹤此次减持前持有银诺医药-B好仓2919.11万股，占比6.95%；减持后持股量为2479.11万股，好仓比例降至5.9%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197227945","title":"银诺医药-B：Cowin Capital Investment III Limited减持，好仓比例降至3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197227945","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197227945?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:33","pubTimestamp":1788860036,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment III Limited于2026年9月8日以每股均价3.6117港元卖出银诺医药-B股份337.00万股，涉资约1217.14万港元。Cowin Capital Investment III Limited此次减持前持有银诺医药-B好仓1778.64万股，占比4.23%；减持后持股量为1441.64万股，好仓比例降至3.43%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129685377","title":"银诺医药-B：Cowin Capital Investment Limited减持，好仓比例降至3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129685377","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129685377?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:33","pubTimestamp":1788860023,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment Limited于2026年9月8日以每股均价3.6117港元卖出银诺医药-B股份337.00万股，涉资约1217.14万港元。Cowin Capital Investment Limited此次减持前持有银诺医药-B好仓1778.64万股，占比4.23%；减持后持股量为1441.64万股，好仓比例降至3.43%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128355022","title":"银诺医药-B：Cowin China Growth Fund II, L.P.减持，好仓比例降至3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128355022","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128355022?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:24","pubTimestamp":1788859488,"startTime":"0","endTime":"0","summary":"于2026年9月8日，Cowin China Growth Fund II, L.P.以每股均价3.6117港元卖出银诺医药-B股份337.00万股，涉资约1217.14万港元。Cowin China Growth Fund II, L.P.此次减持前持有银诺医药-B好仓1778.64万股，占比4.23%；减持后持股量为1441.64万股，好仓比例降至3.43%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665182313","title":"银诺医药-B(02591)：创始人及多名高级管理层作出自愿禁售承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2665182313","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665182313?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:26","pubTimestamp":1788773218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，本公司董事会已获本集团创始人、本公司董事长、执行董事、总经理兼本公司主要股东WANG QINGHUA博士(Wang博士);执行董事、香港医韵医药技术有限公司股东兼本公司雇员激励平台广州诺帕企业管理合伙企业(有限合伙)(广州诺帕)的有限合伙人姜帆女士(姜女士);执行董事兼广州诺帕的有限合伙人徐文洁女士(徐女士);及执行董事兼广州诺帕的有限合伙人黄","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160134448","title":"银诺医药-B（02591）高管自愿再锁定股份6个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1160134448","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160134448?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:25","pubTimestamp":1788773150,"startTime":"0","endTime":"0","summary":"2026年9月7日，广州银诺医药集团股份有限公司宣布，公司创始人及多名高级管理层自愿延长禁售期六个月。上述人员已分别承诺，自2026年8月15日起，连续六个月内不出售其所直接或间接持有的任何银诺医药-B股份或相关权益。公司表示，相关承诺反映管理层对公司未来前景及长期发展的信心。公司提醒投资者及股东在买卖公司证券时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130976354","title":"广州银诺医药集团创始人及高管承诺自2026年8月15日起六个月股份锁定期","url":"https://stock-news.laohu8.com/highlight/detail?id=1130976354","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130976354?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:25","pubTimestamp":1788773109,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司（Innogen Pharmaceutical Group Co.）宣布，公司创始人及高级管理层已承诺自2026年8月15日起实施为期六个月的股份锁定期。此举彰显了核心团队对公司长期发展前景的坚定信心，同时也有助于稳定市场预期，传递出积极的治理信号。锁定期安排从8月中旬正式启动，届时相关方将在此期间不转让或处置所持股份，以进一步维护股东利益并支持公司战略稳步推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664933930","title":"Cowin China Growth Fund II, L.P.减持银诺医药-B(02591.HK)287万股 每股作价约3.64港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664933930","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664933930?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:19","pubTimestamp":1788520744,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160865595","title":"银诺医药-B：Cowin Capital Investment III Limited减持，好仓比例降至4.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160865595","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160865595?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:51","pubTimestamp":1788515507,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment III Limited于2026年9月3日以每股均价3.6397港元卖出银诺医药-B股份287.00万股，涉资约1044.59万港元。Cowin Capital Investment III Limited此次减持前持有银诺医药-B好仓2065.64万股，占比4.91%；减持后持股量为1778.64万股，好仓比例降至4.23%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119293795","title":"银诺医药-B：Cowin China Growth Fund II, L.P.减持，好仓比例降至4.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119293795","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119293795?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:33","pubTimestamp":1788514406,"startTime":"0","endTime":"0","summary":"Cowin China Growth Fund II, L.P.于2026年9月3日以每股均价3.6397港元卖出银诺医药-B股份287.00万股，涉资约1044.59万港元。Cowin China Growth Fund II, L.P.此次减持前持有银诺医药-B好仓2065.64万股，占比4.91%；减持后持股量为1778.64万股，好仓比例降至4.23%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165427375","title":"银诺医药-B：Cowin Capital Investment II LTD减持，好仓比例降至4.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165427375","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165427375?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:20","pubTimestamp":1788513645,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment II LTD于2026年9月3日以每股均价3.6397港元卖出银诺医药-B股份287.00万股，涉资约1044.59万港元。Cowin Capital Investment II LTD此次减持前持有银诺医药-B好仓2065.64万股，占比4.91%；减持后持股量为1778.64万股，好仓比例降至4.23%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innogenpharm.com","stockEarnings":[{"period":"1week","weight":0.0899},{"period":"1month","weight":-0.0125},{"period":"3month","weight":-0.5142},{"period":"6month","weight":-0.8157},{"period":"1year","weight":-0.8924},{"period":"ytd","weight":-0.8714}],"compareEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":-0.0215},{"period":"3month","weight":-0.0029},{"period":"6month","weight":-0.0646},{"period":"1year","weight":-0.0768},{"period":"ytd","weight":-0.053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州银诺医药集团股份有限公司是一家主要从事医药产品的研发及商业化的中国投资控股公司。该公司主要从事商业化原研人源长效胰高血糖素样肽-1（GLP-1）受体激动剂。该公司致力于开发糖尿病和其他代谢性疾病的疗法。该公司的主要产品依苏帕格鲁肽α（商品名：怡诺轻）用于治疗2型糖尿病（T2D）。该公司的主要候选药物管线产品包括YN014、YN401、YN209、YN203和YN202。该公司主要在国内市场经营其业务。","exchange":"SEHK","name":"银诺医药-B","nameEN":"INNOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"银诺医药-B,02591,银诺医药-B股票,银诺医药-B股票老虎,银诺医药-B股票老虎国际,银诺医药-B行情,银诺医药-B股票行情,银诺医药-B股价,银诺医药-B股市,银诺医药-B股票价格,银诺医药-B股票交易,银诺医药-B股票购买,银诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}